This Week at FDA: Dueling mifepristone rulings, CBER head makes executive decision, and more
This Week at FDAMichael Mezher • Ferdous Al-Faruque
APIsBiologics/ biosimilars/ vaccinesBiotechnologyCombination products/companion diagnosticsDiagnostics/IVDsMedical DevicesNorth AmericaNutritional/Natural HealthOTCOtherPharmaceuticalsRegulatory Intelligence/Policy